FGEN
Price
$0.33
Change
+$0.02 (+6.45%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
32.29M
17 days until earnings call
INSM
Price
$68.94
Change
-$1.86 (-2.63%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
12.54B
6 days until earnings call
Ad is loading...

FGEN vs INSM

Header iconFGEN vs INSM Comparison
Open Charts FGEN vs INSMBanner chart's image
FibroGen
Price$0.33
Change+$0.02 (+6.45%)
Volume$10.45K
Capitalization32.29M
Insmed
Price$68.94
Change-$1.86 (-2.63%)
Volume$44.87K
Capitalization12.54B
FGEN vs INSM Comparison Chart
Loading...
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FGEN vs. INSM commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGEN is a Buy and INSM is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (FGEN: $0.31 vs. INSM: $70.74)
Brand notoriety: FGEN and INSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FGEN: 12% vs. INSM: 74%
Market capitalization -- FGEN: $30.23M vs. INSM: $12.54B
FGEN [@Biotechnology] is valued at $30.23M. INSM’s [@Biotechnology] market capitalization is $12.54B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FGEN’s FA Score shows that 0 FA rating(s) are green whileINSM’s FA Score has 1 green FA rating(s).

  • FGEN’s FA Score: 0 green, 5 red.
  • INSM’s FA Score: 1 green, 4 red.
According to our system of comparison, INSM is a better buy in the long-term than FGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FGEN’s TA Score shows that 4 TA indicator(s) are bullish while INSM’s TA Score has 5 bullish TA indicator(s).

  • FGEN’s TA Score: 4 bullish, 3 bearish.
  • INSM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, FGEN is a better buy in the short-term than INSM.

Price Growth

FGEN (@Biotechnology) experienced а +10.84% price change this week, while INSM (@Biotechnology) price change was +0.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

FGEN is expected to report earnings on Aug 11, 2025.

INSM is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($12.5B) has a higher market cap than FGEN($32.3M). INSM YTD gains are higher at: -0.116 vs. FGEN (-41.889). FGEN has higher annual earnings (EBITDA): -101.15M vs. INSM (-818.79M). INSM has more cash in the bank: 1.43B vs. FGEN (131M). FGEN has less debt than INSM: FGEN (79.3M) vs INSM (1.15B). INSM has higher revenues than FGEN: INSM (364M) vs FGEN (180M).
FGENINSMFGEN / INSM
Capitalization32.3M12.5B0%
EBITDA-101.15M-818.79M12%
Gain YTD-41.889-0.11636,149%
P/E RatioN/AN/A-
Revenue180M364M49%
Total Cash131M1.43B9%
Total Debt79.3M1.15B7%
FUNDAMENTALS RATINGS
FGEN vs INSM: Fundamental Ratings
FGEN
INSM
OUTLOOK RATING
1..100
68
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
10017
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8539
P/E GROWTH RATING
1..100
43100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INSM's Valuation (87) in the Biotechnology industry is in the same range as FGEN (94). This means that INSM’s stock grew similarly to FGEN’s over the last 12 months.

INSM's Profit vs Risk Rating (17) in the Biotechnology industry is significantly better than the same rating for FGEN (100). This means that INSM’s stock grew significantly faster than FGEN’s over the last 12 months.

INSM's SMR Rating (100) in the Biotechnology industry is in the same range as FGEN (100). This means that INSM’s stock grew similarly to FGEN’s over the last 12 months.

INSM's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for FGEN (85). This means that INSM’s stock grew somewhat faster than FGEN’s over the last 12 months.

FGEN's P/E Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for INSM (100). This means that FGEN’s stock grew somewhat faster than INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FGENINSM
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 10 days ago
71%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 17 days ago
74%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PANL4.240.19
+4.69%
Pangaea Logistics Solutions Ltd
DUOT6.140.24
+4.07%
Duos Technologies Group
GKOS92.612.88
+3.21%
Glaukos Corp
YUM146.161.11
+0.77%
Yum! Brands
ARDX4.840.03
+0.52%
Ardelyx

FGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, FGEN has been loosely correlated with AVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FGEN jumps, then AVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FGEN
1D Price
Change %
FGEN100%
+2.70%
AVTX - FGEN
57%
Loosely correlated
+1.64%
AXON - FGEN
43%
Loosely correlated
+3.82%
BMRN - FGEN
41%
Loosely correlated
+0.72%
INSM - FGEN
39%
Loosely correlated
-0.70%
CMRX - FGEN
35%
Loosely correlated
N/A
More

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
-2.60%
THAR - INSM
74%
Closely correlated
-0.02%
AGIO - INSM
45%
Loosely correlated
+3.14%
SRPT - INSM
44%
Loosely correlated
+3.82%
VERA - INSM
41%
Loosely correlated
+5.06%
AXON - INSM
40%
Loosely correlated
+2.39%
More